J3R-MC-YDAL - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
Phase 3 – large-scale trial before approval
Conditions:
Overweight
Obesity
Sponsor: Eli Lilly & Co.
trial.available_in:
БГ
Overview
Trial status: Authorised
Percent Change from Baseline in Body Weight [Time Frame: Baseline, Week 64]
Who can participate
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 238 participants
БГ